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ABSTRACT 
INTRODUCTION 
Cardiovascular disease is a major health problem across the world. By the year 2020, 
Ischemic Heart Disease will be the most common cause of death worldwide. 
Detection of Coronary artery disease at the ischemic stage helps in preventing the 
progression of disease.  ECG plays an important role in the diagnosis of AMI. But 10 
to 20% of ECG shows normal findings in CAD. In these cases, cardiac markers help 
in the diagnosis.Troponin and CK-MB are currently used biomarkers for diagnosing 
cardio myocyte injury. But these markers tend to elevate after 6 hours of cardiac 
injury. Heart Type Fatty Acid Binding Protein (HFABP) is abundant in myocardium 
and rapidly released from cardiomyocytes into blood. It appears in plasma within 2 
hours of cardiac damage. Because of its low molecular weight, relative tissue 
specificity and high myocardial content, this marker is released earlier than other 
markers. 
AIM & OBJECTIVES: 
The aim of our study is to estimate the level of HFABP in CAD patients and its 
correlation with CK-MB and Lipid profile. 
METHODS 
After getting approval from the Institutional Ethical Committee, this study was 
conducted at K.A.P.V. Govt. Medical College and MGMGH, Tiruchirappalli during 
the period of June 2015 to June 2016. This age matched cross sectional study included 
90 subjects. Study group included 45 patientsadmitted in ICCU within 6 hours of 
onset of chest pain and diagnosed to have coronary artery disease and 45 healthy 
individuals as controls.HFABP was estimated by ELISA method. CK-MB was done 
by immune inhibition method. Total cholesterol and TGL were estimated by 
enzymatic methods. HDL was estimated by selective inhibition method (Direct 
method). 
 
RESULTS  
The Mean value of HFABP in study and control groups were 35.811 ± 19.2871 and 
2.787 ± 1.4556 and the p value was 0.000 (<0.05), which was statistically significant. 
When compared to CK-MB, HFABP showed 76.5% detection in first 3 hours where 
as CK-MB had only 58.8%. There was also a positive correlation found between 
HFABP with CK-MB and duration. 
CONCLUSION 
In this study, elevated HFABP in the early hours (0 to 3 hours) of onset of ischemic 
chest pain clearly shows that serum HFABP can be used as an early marker in the 
diagnosis of coronary artery disease and plays a major role in the management of 
CAD. 
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